Moleculin Announces Enrollment Opens for Brain Tumor Trial of WP1066
July 31 2018 - 7:30AM
Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the
"Company"), a clinical stage pharmaceutical company focused on the
development of oncology drug candidates, all of which are based on
license agreements with The University of Texas System on behalf of
the M.D. Anderson Cancer Center, today announced enrollment has
opened for a physician-sponsored clinical trial of WP1066 for the
treatment of glioblastoma and brain metastases in adults.
“We have been eagerly awaiting the beginning of this physician
sponsored clinical trial,” commented Walter Klemp, Chairman and CEO
of Moleculin. “The trial, which is now listed on clinicaltrials.gov
and being conducted at MD Anderson Cancer Center, is now open for
enrollment. This is our first investigator initiated trial of
WP1066 and an important milestone. Given the unique potential
of WP1066, we expect more trials to follow.”
The goal of this clinical research study is to find the highest
tolerable dose of WP1066 that can be given to patients with
recurrent (has returned after treatment) cancerous brain tumors or
melanoma that has spread to the brain. The safety of this drug will
also be studied.
WP1066 is designed to target the STAT3 pathway in cancer cells,
which makes these cells divide, increases new blood vessels to the
tumor, causes the cancer cells to move throughout the body and
brain, and avoids them being detected by the immune system. We
believe that targeting this pathway may cause the immune system to
kill the cancer cells.
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical stage
pharmaceutical company focused on the development of oncology drug
candidates, all of which are based on discoveries made at M.D.
Anderson Cancer Center. Our clinical stage drugs are Annamycin, an
anthracycline designed to avoid multidrug resistance mechanisms
with little to no cardiotoxicity being studied for the treatment of
relapsed or refractory acute myeloid leukemia, more commonly
referred to as AML, and WP1066, an immuno-stimulating STAT3
inhibitor targeting brain tumors, pancreatic cancer and AML. We are
also engaged in preclinical development of additional drug
candidates, including additional STAT3 inhibitors and compounds
targeting the metabolism of tumors.
For more information about the Company, please visit
http://www.moleculin.com.
Forward-Looking Statements
Some of the statements in this release are
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, Section 21E of the Securities Exchange Act
of 1934 and the Private Securities Litigation Reform Act of 1995,
which involve risks and uncertainties. Forward-looking statements
in this press release include, without limitation, the ability of
MD Anderson to recruit patients for the WP1066 clinical trial, the
ability of WP1066 to show safety and efficacy in patients and
whether additional clinical trials will occur. Although Moleculin
Biotech believes that the expectations reflected in such
forward-looking statements are reasonable as of the date made,
expectations may prove to have been materially different from the
results expressed or implied by such forward-looking statements.
Moleculin Biotech has attempted to identify forward-looking
statements by terminology including ''believes,'' ''estimates,''
''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,''
''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,''
''approximately'' or other words that convey uncertainty of future
events or outcomes to identify these forward-looking statements.
These statements are only predictions and involve known and unknown
risks, uncertainties, and other factors, including those discussed
under Item 1A. "Risk Factors" in our most recently filed Form 10-K
filed with the Securities and Exchange Commission (“SEC”) and
updated from time to time in our Form 10-Q filings and in our other
public filings with the SEC. Any forward-looking statements
contained in this release speak only as of its date. We undertake
no obligation to update any forward-looking statements contained in
this release to reflect events or circumstances occurring after its
date or to reflect the occurrence of unanticipated events.
ContactsJoe Dorame, Robert Blum or Joe
DiazLytham Partners, LLC602-889-9700mbrx@lythampartners.com
Moleculin Biotech (NASDAQ:MBRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Moleculin Biotech (NASDAQ:MBRX)
Historical Stock Chart
From Sep 2023 to Sep 2024